On August 22, 2025 Santo Therapeutics and Luca Healthcare, Inc./Ltd. (hereinafter referred to as " Luca Healthcare ") signed a strategic cooperation agreement to explore and evaluate the application of digital health technology ( DHT ) in the clinical development of cell and gene therapies (such as CAR-T , TCR-T , gene therapy, gene editing, etc.), including remote monitoring and patient-centered data collection; and to jointly develop and validate AI capabilities for early warning of safety events such as cytokine release syndrome ( CRS ) and immune effector cell-related neurotoxicity syndrome ( ICANS ), in order to improve patient safety, trial operation efficiency and evidence generation quality.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Luca Healthcare is a medical technology company focused on digital target development. It is dedicated to developing innovative digital medicine products that integrate advanced artificial intelligence with medical knowledge to analyze and identify behavioral and physiological characteristics associated with a variety of diseases. Leveraging its clinically proven technology platform, LucaPlex , the company provides patients, healthcare professionals, and life science companies with clinical-grade digital solutions covering screening, diagnosis, management, and treatment. The aim is to optimize treatment pathways through proactive intervention in disease progression, ultimately improving patient clinical benefits.
In vivo CAR-T therapy is currently a hot research topic in the biomedical field. Existing literature reports that while this therapy can bring good efficacy, it is also accompanied by some common clinical toxicities, such as cytokine release syndrome (CRS ); immune effector cell-related neurotoxicity syndrome (ICANS) with altered consciousness, tremor, and headache; hematological toxicities such as neutropenia, leukopenia, thrombocytopenia, and lymphopenia; and pulmonary infections (such as bacterial, fungal, and viral infections). The occurrence of these toxicities is closely related to the activation and proliferation of T cells, the massive release of cytokines, and the impact of treatment on the immune system. Therefore, early prediction, dynamic monitoring, and precise intervention of these toxic side effects are extremely important.
Based on this strategic consensus , the collaboration between the two parties will focus on AI health technologies related to in vivo CAR-T , aiming to empower precise management of its safety and tolerability through innovative algorithms, and comprehensively improve the clinical control level of treatment and patient benefits.
Both leaders expressed high expectations and confidence in this cooperation.
Luca Healthcare CEO Mr. Chen stated: "We are very honored to collaborate with Syntop Biotech. As the cornerstone of future cancer treatment, CAR-T therapy and rehabilitation align perfectly with our vision of empowering assessment and disease management through digital targets. We look forward to accelerating innovation together and opening up new hope for patients."
Dr. Zhou Lu, CEO of Syntop Biotech , also stated, " AI and in vivo CAR-T are both future development directions in the pharmaceutical industry. Syntop is honored to have the opportunity to collaborate with Luca Healthcare and contribute our modest efforts to bringing safer treatments to cancer patients."